Recent News

• 12.08.2025 - Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
• 12.02.2025 - Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
• 11.24.2025 - Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
• 11.19.2025 - Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
• 11.18.2025 - Harmony Biosciences to Participate in Upcoming Investor Conferences
• 11.04.2025 - Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
• 10.23.2025 - Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
• 09.24.2025 - Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
• 09.24.2025 - Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Recent Filings

• 12.05.2025 - 144 Report of proposed sale of securities
• 11.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - EX-99.1 EX-99.1
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - 8-K Current report
• 10.23.2025 - 8-K Current report
• 10.23.2025 - EX-99.1 EX-99.1